These pleiotropic mechanisms position PCSK9 at the intersection of dyslipidemia, inflammation, and thrombosis—key drivers of ischemic stroke, which remains a leading cause of mortality and long‐term disability worldwide [3, 4, 5]. Here, PCSK9 is linked to metabolic syndrome.